Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study

Podobne zapisy

• Authors’ Reply to Kamel et al.: “Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study”
  od: Glund, Stephan, i wsp.
  Wydane: (2016)
• Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran
  od: Glund, Stephan, i wsp.
  Wydane: (2019)
• Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies
  od: Norris, Stephen, i wsp.
  Wydane: (2017)
• The Renal Elimination Pathways of the Dabigatran Reversal Agent Idarucizumab and its Impact on Dabigatran Elimination
  od: Glund, Stephan, i wsp.
  Wydane: (2018)
• Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study
  od: Yasaka, Masahiro, i wsp.
  Wydane: (2017)